Arbutus Biopharma Corporation (ABUS)

2,7300 +0,0100 (+0,37%) Ab 12:30PM EDT. Markt geöffnet.

Arbutus Biopharma Corporation

701 Veterans Circle
Warminster, PA 18974
United States
267 469 0914
https://www.arbutusbio.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 73

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Michael J. McElhaugh	Co-Founder, Interim President, CEO & Director	644,4k	N/A	1975
Dr. Michael J. Sofia Ph.D.	Chief Scientific Officer	656,1k	N/A	1958
Mr. David C. Hastings CPA	CFO & Chief Accounting Officer	647,1k	N/A	1961
Ms. Lisa M. Caperelli	Vice President of Investor Relations	N/A	N/A	N/A
Mr. J. Christopher Naftzger BA, Esq., J.D.	General Counsel, Chief Compliance Officer & Secretary	N/A	N/A	1967
Ms. Shannon Briscoe SPHR	Vice President of Human Resources	N/A	N/A	N/A
Dr. Karen Sims M.D., Ph.D.	Chief Medical Officer	N/A	N/A	1971
Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C.	Corporate Secretary	N/A	N/A	1951

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Corporate Governance

Arbutus Biopharma Corporations ISS Governance QualityScore, Stand 1. April 2024, lautet 6. Die grundlegenden Scores sind Audit: 3, Vorstand: 6, Shareholderrechte: 9, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.